Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ciliopathy and Centrosome-Targeted Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CC2D2B drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CC2D2B Recombinant Protein (C2 Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW confirmed by MS. |
View CC2D2B Products |
| Gene Delivery | CC2D2B Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and localization assays. |
View CC2D2B Products |
| Benchmark Ab | Anti-CC2D2B Recombinant Antibody Sequence-verified control antibody for immunofluorescence and western blot validation. |
View CC2D2B Products |
| Validator | CC2D2B siRNA Set For target knockdown and functional validation in ciliary assembly assays. |
View CC2D2B Products |
| Related Target A | CC2D2A Critical homolog sharing high sequence identity; essential for off-target selectivity screening. |
View CC2D2A Products |
| Related Target B | CEP290 Key ciliary transition zone protein cooperating with CC2D2B in ciliopathy pathways. |
View CEP290 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homology-driven off-target effects (CC2D2A vs. CC2D2B) | High-purity recombinant CC2D2A and CC2D2B proteins available for cross-reactivity profiling. |
| Intracellular localization & ciliary targeting complexity | Lentiviral vectors optimized for stable expression in ciliated cell lines (e.g., hTERT-RPE1). |
| Lack of reliable positive control reagents | Sequence-verified recombinant detection antibodies with high batch-to-batch consistency. |
| Assay noise from degraded protein constructs | Strict quality control ensuring >95% purity and correct theoretical molecular weight. |
Live CC2D2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the primary cilium and centrosomal machinery is an emerging frontier in both oncology and genetic medicine. CC2D2B (Coiled-Coil and C2 Domain Containing 2B) plays a critical structural role at the ciliary transition zone, regulating protein entry and exit from the ciliary compartment. Disruptions in this machinery are heavily implicated in ciliopathies (such as Joubert syndrome) and are increasingly linked to centrosomal amplification in solid tumors.
The race for CC2D2B therapeutics is intensifying, with major players shifting focus from traditional diagnostics to small-molecule inhibitors of C2-domain-mediated membrane binding and gene therapies for ciliopathy correction. As first-generation ciliary transition zone modulators reach preclinical validation, the next wave of R&D is targeting the specific protein-protein interactions (PPI) of CC2D2B with transition zone complexes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Biotech Startups / Academic Consortia | Solid Tumors (Glioblastoma, Lung) | Binding Affinity Assay (Need high-purity recombinant CC2D2B domains) |
| Gene Therapy (AAV/Lentivirus) | Orphan Drug Developers | Ciliopathies (Joubert/Meckel-like) | Functional Rescue Validation (Need Lentivirus for stable cell line generation) |
| RNA Therapeutics (ASO/siRNA) | RNAi Therapeutics Specialists | Centrosome-amplified Cancers | Knockdown Efficiency Verification (Need validated siRNA and qPCR controls) |